Arbutus Biopharma (ABUS) Other Non-Current Assets (2019 - 2026)

Arbutus Biopharma has disclosed Other Non-Current Assets across 8 years of filings, most recently posting $131000.0 for Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $131000.0, up 285.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $131000.0 (up 285.29% YoY), and the FY2025 annual result was $130000.0, up 282.35% from the prior year.
• Other Non-Current Assets came in at $131000.0 for Q1 2026 at Arbutus Biopharma, up from $130000.0 in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $190000.0 in Q1 2022 to a low of $3000.0 in Q3 2023.
• The 5-year median for Other Non-Current Assets is $116500.0 (2022), against an average of $98000.0.
• Across the five-year window, Other Non-Current Assets tumbled 98.2% in 2023 and surged 285.29% in 2026, its largest moves.
• Arbutus Biopharma's Other Non-Current Assets stood at $103000.0 in 2022, then tumbled by 97.09% to $3000.0 in 2023, then soared by 1033.33% to $34000.0 in 2024, then jumped by 282.35% to $130000.0 in 2025, then gained by 0.77% to $131000.0 in 2026.
• The last three Other Non-Current Assets figures came in at $131000.0 (Q1 2026), $130000.0 (Q4 2025), and $131000.0 (Q3 2025), per Business Quant data.